Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.42 |
| ▸ | AURKA | O14965 | 7/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990852 | 0.88 | PLK4 (0.69) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18165810 | 0.85 | PLK4 (0.73) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL19990899 | 0.80 | PLK4 (0.72) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18154811 | 0.79 | PLK4 (0.73) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18154758 | 0.79 | PLK4 (0.73) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18154739 | 0.79 | PLK4 (0.73) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18154687 | 0.78 | PLK4 (0.75) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18166073 | 0.78 | PLK4 (0.86) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL19990643 | 0.77 | PLK4 (0.70) | PLK4AURKBAURKASRCGSK3B | |
| SCHEMBL18166037 | 0.77 | PLK4 (0.62) | PLK4AURKBAURKASRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752612-B2 | PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20180086739-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086739-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086739-A1 | PLK4 INHIBITORS | PLK4, PLK2, PLK3 | PLK4 1/4885AURKB 23/4885AURKA 32/4885 |
| US-10752612-B2 | PLK4 inhibitors | PLK4, PLK2, PLK3 | PLK4 1/4885AURKB 23/4885AURKA 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.